Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway and Improve the Treatment Outcomes of Haematological Malignancies - A Translation Bench Study

NCT04234022 is registered in ClinicalTrials.gov with The Royal Wolverhampton Hospitals NHS Trust as lead sponsor.

NCT NCT04234022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04234022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway and Improve the Treatment Outcomes of Haematological Malignancies - A Translation Bench Study
Lead sponsor
The Royal Wolverhampton Hospitals NHS Trust
Phase
Observational
Overall status
Recruiting
Start date
October 22, 2021
Completion date
December 31, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma